v3.25.2
Schedule of Net Loss Per Share Basic and Diluted (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Earnings Per Share [Abstract]        
Net loss $ (4,439) $ (11,005) $ (31,347) $ (21,617)
Deemed dividend on Series A and Series A-1 Convertible Preferred Stock (7,496)
Series B and Series B-1 Convertible Preferred Stock dividends earned (3,449) (12,559)
Net loss attributable to Lucid Diagnostics Inc. common stockholders $ (7,888) $ (11,005) $ (43,906) $ (29,113)
Weighted average common shares outstanding, basic 98,989,161 48,212,040 83,976,182 46,613,362
Weighted average common shares outstanding, diluted 98,989,161 48,212,040 83,976,182 46,613,362
Net loss per share - basic [1] $ (0.08) $ (0.23) $ (0.52) $ (0.62)
Net loss per share - diluted [1] $ (0.08) $ (0.23) $ (0.52) $ (0.62)
[1] - Convertible Preferred Stock would potentially be considered a participating security under the two-class method of calculating net loss per share. However, the Company has incurred net losses to-date, and as such holders are not contractually obligated to share in the losses, there is no impact on the Company’s net loss per share calculation for the periods indicated.